急性髓细胞白血病患者CD96和CD123的表达及对预后的意义*

Clinical significance of CD96 and CD123 in acute myelocytic leukemia*

摘要:

目的 检测CD96、CD123在急性髓细胞白血病（AML）患者中的表达，探讨其与AML疗效和预后的关系。方法 选取156例AML患者为观察对象，选取同期该院健康体检者150例作为对照组。采用流式细胞术检测CD96、CD123表达情况，并分析CD96、CD123表达与化疗疗效的关系。结果 AML患者CD96、CD123的阳性表达率与对照组比较，差异有统计学意义（P?<0.05）；AML患者中CD96、CD123阳性表达的缓解率均低于阴性表达者（P?<0.05）；AML患者中CD96、CD123阳性表达的生存率均低于阴性表达者（P?< 0.05）；AML患者中CD96、CD123阳性表达的化疗后感染、化疗后复发发生率均高于阴性表达者（P?<0.05）；AML患者中CD96、CD123阳性表达的中位生存期均低于阴性表达者（P?<0.05）。结论 CD96、CD123在AML中均有不同程度的表达，其阳性表达可能与原发耐药或复发进展有关，可作为判断AML患者预后的相关指标。

Abstract:

Objective To study the expression of CD96 and CD123 in acute myelocytic leukemia (AML) patients and their potential clinical significance. Methods Totally 156 AML patients were selected as subjects. Flow cytometry was performed to detect the expression of CD96 and CD123. Relationship between CD96/CD123 and clinical characteristics were analyzed. Results The positive expression rates of CD96 and CD123 were significantly increased in AML group when compared with control group (P?